Edition:
United Kingdom

Catalent Inc (CTLT.N)

CTLT.N on New York Stock Exchange

55.77USD
20 Aug 2019
Change (% chg)

$-0.48 (-0.85%)
Prev Close
$56.25
Open
$56.22
Day's High
$56.22
Day's Low
$55.53
Volume
148,103
Avg. Vol
217,057
52-wk High
$58.38
52-wk Low
$29.26

About

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $8,219.79
Shares Outstanding(Mil.): 145.72
Dividend: --
Yield (%): --

Financials

  CTLT.N Industry Sector
P/E (TTM): 56.74 29.73 33.85
EPS (TTM): 0.99 -- --
ROI: 3.52 13.04 12.69
ROE: 10.41 14.12 17.13

BRIEF-Catalent Biologics Announces Agreement To Provide Production For Spinal Muscular Atrophy

* CATALENT INC. - CATALENT ANNOUNCES AGREEMENT TO PROVIDE PRODUCTION FOR SPINAL MUSCULAR ATROPHY

16 Jul 2019

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion (916.4 million pounds) in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

15 Apr 2019

Catalent seeks slice of gene therapy market with Paragon buy

Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

15 Apr 2019

UPDATE 3-Catalent seeks slice of gene therapy market with Paragon buy

April 15 Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.

15 Apr 2019

Catalent to buy Paragon Bioservices for $1.2 bln

April 15 Catalent Inc said on Monday it would buy privately held gene therapy-focused Paragon Bioservices Inc in an all-cash deal for $1.2 billion.

15 Apr 2019

PRESS DIGEST- Wall Street Journal - April 15

April 15 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

15 Apr 2019

Catalent to buy Paragon Bioservices for $1.2 billion: WSJ

Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

15 Apr 2019

UPDATE 1-Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

April 14 Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

15 Apr 2019

Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

April 14 Drug developer Catalent Inc has agreed to buy privately held Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

14 Apr 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates